Overview

He is an active member of the international standards organization International Electrochemical Commission/International Special Committee on Radio Interference and is the U.S. technical advisor to CISPR Subcommittee B in charge of developing international radiofrequency interference standards for industrial, scientific, and medical devices. Terry has extensive knowledge on international EMC and radio regulations and spectrum allocations for many types of licensed and unlicensed communications technologies. He also represents the American National Standards Institute C63 Committee before the FCC and other federal agencies on various radiofrequency interference matters involving digital devices and many types of RF emitters.

His FDA practice involves pharmaceutical and medical device approvals with special emphasis on drug exclusivities and patent protection under Hatch-Waxman; “safe harbor” counseling and patent term extension applications; and biosimilar approvals, brand exclusivities, and patent litigation procedures under the Biologics Price Competition and Innovation Act. In 2018, Terry gave testimony on these topics before the U.S. Senate Special Committee on Aging. He spoke to the committee about drug patenting and pricing, particularly as they relate to biosimilar pharmaceuticals.

Terry also has extensive experience in the regulation of digital health, telemedicine, and wireless medical device technologies. He is on the advisory board for the Bloomberg BNA Pharmaceutical Law and Industry Report.